Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
暂无分享,去创建一个
E. Schuuring | E. Smit | A. Dingemans | R. Mathijssen | A. Huitema | W. Timens | V. Retèl | M. M. van den Heuvel | D. Touw | N. Steeghs | J. V. van Boven | A. D. de Langen | R. ter Heine | A. van der Wekken | M. Paats | L. Hendriks | S. Hashemi | S. Croes | M. B. Muntinghe-Wagenaar | M. Lopez-Yurda | Marinda Meertens | Barend J. Sikkema | B. J. Sikkema